T4202

Delamanid (OPC-67683) is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall.

(Rac)-Etavopivat ((Rac)-FT-4202), an isomer of Etavopivat, is an orally active erythrocyte pyruvate kinase-R (PKR) activator used in sickle cell disease and haemoglobinopathy research [1].

Etavopivat is a potent, selective, and orally active activator of erythrocyte pyruvate kinase (PKR) that enhances red blood cell glycolytic flux and energy metabolism, exhibiting strong antisickling effects by improving erythrocyte deformability and reducing hemoglobin polymerization. Etavopivat is therefore widely applied in translational and mechanistic studies of sickle cell disease and other inherited haemoglobinopathies.

Delamanid-D4 is deuterium-labeled Delamanid. Delamanid (T4202) is a newer mycobacterial cell wall synthesis inhibitor that inhibits the synthesis of mucus acid.